Regenerative Medical Technology (RMTG) Gross Margin (2018 - 2025)
Historic Gross Margin for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to 42.49%.
- Regenerative Medical Technology's Gross Margin fell 332600.0% to 42.49% in Q3 2025 from the same period last year, while for Sep 2025 it was 59.76%, marking a year-over-year decrease of 111500.0%. This contributed to the annual value of 68.73% for FY2024, which is 8000.0% down from last year.
- Per Regenerative Medical Technology's latest filing, its Gross Margin stood at 42.49% for Q3 2025, which was down 332600.0% from 59.56% recorded in Q2 2025.
- Regenerative Medical Technology's 5-year Gross Margin high stood at 75.74% for Q3 2024, and its period low was 232.88% during Q1 2021.
- In the last 5 years, Regenerative Medical Technology's Gross Margin had a median value of 64.88% in 2024 and averaged 43.0%.
- Per our database at Business Quant, Regenerative Medical Technology's Gross Margin plummeted by -2258200bps in 2021 and then surged by 2684500bps in 2022.
- Regenerative Medical Technology's Gross Margin (Quarter) stood at 31.69% in 2021, then soared by 100bps to 63.37% in 2022, then grew by 11bps to 70.63% in 2023, then fell by -8bps to 64.88% in 2024, then plummeted by -35bps to 42.49% in 2025.
- Its last three reported values are 42.49% in Q3 2025, 59.56% for Q2 2025, and 69.18% during Q1 2025.